Generics for Xeljanz (Tofacitinib) are being approved one after another. After crystalline form patent was deleted from the list, it seems that domestic companies are competitively receiving generic licenses.

According to the MFDS on the 9th, until this day, a total of 42 generics for Xeljanz have been licensed. Since Boryung's generic was first approved in August of last year, it has continued steadily.

Generics have increased rapidly since last December. After GL Pharma on December 23, in about a month or two, 31 companies were granted generic licenses.

About half of these are companies that commissioned production to Boryung. Boryung plans to consign products from 16 co